Search Result

Results for "

pancreatic ductal adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Akt (1) Apoptosis (5) Autophagy (2) c-Myc (1) Calcium Channel (2) Caspase (2) Cholecystokinin Receptor (1) Epigenetic Reader Domain (2) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Ferroptosis (1) HDAC (1) Interleukin Related (1) MDM-2/p53 (1) MMP (2) mTOR (1) NAMPT (1) Nuclear Hormone Receptor 4A/NR4A (1) Orexin Receptor (OX Receptor) (2) Phosphatase (1) Ras (1) Reactive Oxygen Species (1) Ribosomal S6 Kinase (RSK) (1) Sirtuin (1)
By Research Areas:	Cancer (19) Endocrinology (3) Infection (1) Inflammation/Immunology (3) Neurological Disease (4)

By Targets:

ADC Cytotoxin (1)

Akt (1)

Apoptosis (5)

Autophagy (2)

c-Myc (1)

Calcium Channel (2)

Caspase (2)

Cholecystokinin Receptor (1)

Epigenetic Reader Domain (2)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

Ferroptosis (1)

HDAC (1)

Interleukin Related (1)

MDM-2/p53 (1)

MMP (2)

mTOR (1)

NAMPT (1)

Nuclear Hormone Receptor 4A/NR4A (1)

Orexin Receptor (OX Receptor) (2)

Phosphatase (1)

Ras (1)

Reactive Oxygen Species (1)

Ribosomal S6 Kinase (RSK) (1)

Sirtuin (1)

By Research Areas:

Cancer (19)

Endocrinology (3)

Infection (1)

Inflammation/Immunology (3)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122723

GOT1 inhibitor-1 1 Publications Verification	Others	Cancer
GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC₅₀ of 8.2 uM. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-P99379

Nidanilimab CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-100498

GSK2256098 2 Publications Verification	FAK Apoptosis	Cancer
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

HY-147838

Nampt-IN-9

NAMPT Cancer

Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .

Nampt-IN-9	NAMPT	Cancer
Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

HY-101194

Tin protoporphyrin IX dichloride Maximum Cited Publications 16 Publications Verification Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX
Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .

HY-N6237

Aspulvinone O	Reactive Oxygen Species	Infection
Aspulvinone O is a natural inhibitor of aspartate transaminase 1 (GOT1). GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 may serve as an important target in PDAC. Aspulvinone O suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism .

HY-160045

AP1153 aptamer sodium	Cholecystokinin Receptor	Cancer
AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-161346

EBET-1055	ADC Cytotoxin Epigenetic Reader Domain	Cancer
EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-135985

DCLK1-IN-1 1 Publications Verification	Others	Cancer
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC₅₀: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 ⁺ pancreatic ductal adenocarcinoma (PDAC) .

HY-148409

MMRi62	Ferroptosis Apoptosis Autophagy MDM-2/p53	Cancer
MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12 .

HY-19808

C-DIM12 1 Publications Verification DIM-C-pPhCl	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease Inflammation/Immunology Cancer
C-DIM12 is a potent, orally active Nurr1 antagonist. C-DIM12 inhibits the tumor growth and autophagy, and induces the cell apoptosis. C-DIM12 has anti-inflammatory and neuroprotective effects, and can be used for cancer and neurological disease study .

HY-120272

SMAP-2

DT-1154
Phosphatase Cancer

SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity .

SMAP-2 DT-1154	Phosphatase	Cancer
SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity .

HY-P1676

cyclo(RLsKDK) BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .

HY-P1676A

cyclo(RLsKDK) TFA BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .

HY-10805

Almorexant 3 Publications Verification ACT 078573	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Neurological Disease Endocrinology Cancer
Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca ²⁺ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

HY-10805A

Almorexant hydrochloride 3 Publications Verification ACT 078573 hydrochloride	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Neurological Disease Endocrinology Cancer
Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca ²⁺ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

HY-136453

CR-1-31-B 5 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells .

cyclo(RLsKDK) TFA BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .

DSTYSLSSTLTLSK	Peptides	Inflammation/Immunology
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

cyclo(RLsKDK) BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .

Nidanilimab CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

Aspulvinone O	Infection Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	Reactive Oxygen Species
Aspulvinone O is a natural inhibitor of aspartate transaminase 1 (GOT1). GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 may serve as an important target in PDAC. Aspulvinone O suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks